NEXT Oncology, an Avacare business

10/24/2025

We were proud to join our colleagues and collaborators at the SPARC Summit—an inspiring forum hosted by Bayer that brought together leaders in early-phase oncology research.

NEXT Oncology is honored to be working with Bayer across five different Phase I trials, advancing innovative cancer therapies through global collaboration. Events like this reflect the shared commitment to accelerating progress in oncology through partnership and scientific exchange.

A big thank you to the Bayer team and all who participated in this impactful event.

hashtag hashtag hashtag hashtag hashtag

09/11/2025

Congratulations to our colleagues at Revolution Medicines on these groundbreaking trials. We are proud to work with you.

https://www.clinicaltrialsarena.com/newsletters/revolution-medicines-daraxonrasib-phase-i-results-2/

09/03/2025

We are happy to welcome Faran S Polani, MD to the NEXT Oncology team in our Dallas office!

08/27/2025

Don't miss this learning opportunity at the 2025 Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer), featuring Anthony Tolcher and Shiraj Sen!

https://ce.horizoncme.com/content/2025-summit-novel-therapeutics-oncology-precision-medicine-cancer-stop-cancer -tabs-node-course-default2

08/14/2025

ICYMI:We’re proud to announce that results from a Phase 1 clinical trial led by Ildefonso Rodriguez-Rivera have been published in Nature Medicine. The study evaluated precemtabart tocentecan (precem-TcT) in collaboration with EMD Serono, Inc. in patients with metastatic colorectal cancer and showed encouraging early activity and manageable safety.

This publication reflects our continued commitment to advancing first-in-human cancer research and improving outcomes for patients with limited treatment options.

Read more here: http://bit.ly/46LssPl

Phase 1 trial findings published in Nature Medicine show promise for a new approach to targeting colorectal cancer and other tumors expressing CEACAM5. NEXT Oncology’s Dr. Ildefonso Ismael Rodriguez Rivera, a medical oncologist and hematologist in the San Antonio office, has led an innovative Phas...

08/07/2025

We’re proud to announce that results from a Phase 1 clinical trial led by Ildefonso Rodriguez-Rivera have been published in Nature Medicine. The study evaluated precemtabart tocentecan (precem-TcT) in collaboration with EMD Serono, Inc. in patients with metastatic colorectal cancer and showed encouraging early activity and manageable safety.

This publication reflects our continued commitment to advancing first-in-human cancer research and improving outcomes for patients with limited treatment options.

Read more here: http://bit.ly/46LssPl

07/29/2025

We are thrilled to announce a partnership with Oncologia D'Or to provide Phase 1 clinical trial options to patients in Brazil. Read more here:

https://nextoncology.com/next-oncology-expands-to-brazil-in-strategic-partnership-with-oncologia-dor-and-idor/

06/27/2025

We were thrilled to celebrate the opening of our newest location in Houston with a fun Grand Opening party.

06/09/2025

Congratulations to our colleagues at Iambic Therapeutics for continued success. Our own Andrae Vandross with NEXT - Austin had this to say: “Patients entering this study, particularly those with brain metastases, have few available treatment options. Our focus is on identifying important potential advances for these individuals and to look at novel approaches that may provide a therapeutic benefit.”

Read more here:

Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment

06/02/2025

We are very honored to support ongoing clinical research at American Society of Clinical Oncology (ASCO) 2025 and the Merit awards. Congratulations to Curtis Perry, recipient of the Anthony and Marilyn Tolcher Merit award and Udhayvia Grewal, recipient of the Theresa Mays Endowed Merit Award, for their outstanding work.

05/28/2025

Congratulations to our colleagues at Biohaven on continuing to advance innovative . Our own Michael Song commented: "We are excited to partner with Biohaven and dose the first patient on this important study. This is an exciting, validated target with potential to extend therapeutic benefit to several FGFR3 driven tumors."

Read more here:

05/20/2025

We are thrilled to announce that our colleague Alex Spira, MD, PhD, FACP, FASCO with NEXT Oncology Virginia has been appointed Chief Scientific Officer for NEXT Oncology worldwide.

Our founder, Anthony Tolcher, had this to say: “We are committed to offering hope when conventional treatments fall short—and that’s what being the NEXT Option is all about. Dr. Spira is a respected leader in the oncology community, and his expertise will be instrumental as we expand our Phase 1 trial capabilities and scientific leadership.”

Read more here: https://nextoncology.com/next-oncology-names-dr-alex-spira-chief-scientific-officer/